Phase
Condition
Hair Loss
Alopecia
Treatment
Jaktinib
placebo
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
participants voluntarily sign the informed consent form (ICF);
Age ≥ 18 years and <65 years, either male or female;
Clinical presentation compatible with alopecia areata with a current episode lastingnot exceeding ≤8 years.
At least 50% scalp hair loss.
Willing to comply with the study visits and requirements of the study protocol.
Exclusion
Exclusion Criteria:
participants has taken a JAK inhibitor prior to randomization;
participants who are unsuitable to the trial, as identified by the investigator.
Study Design
Connect with a study center
Peking University People's Hospital
Beijing, Beijing 100044
ChinaSite Not Available
Hospital for Skin Diseases, Chinese Academy of medical Sciences
Nanjing, Jiangsu 210042
ChinaSite Not Available
No. 12, Jiangwangmiao Street, Xuanwu District
Nanjing, Jiangsu 210042
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.